Recursion Pharmaceuticals (RXRX) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free RXRX Stock Alerts $8.60 -0.04 (-0.46%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRecursion Pharmaceuticals First Quarter 2024 Earnings: Beats Expectationsfinance.yahoo.com - May 11 at 11:58 AMRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up on Better-Than-Expected Earningsamericanbankingnews.com - May 11 at 2:04 AMRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSmarketbeat.com - May 10 at 11:30 PMRecursion Pharmaceuticals CEO explains how AI could make drug development faster and less costlymsn.com - May 10 at 8:54 PMRecursion Pharma's Q1 Earnings Beat Estimatesfool.com - May 10 at 8:54 PMDemystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviewsmarkets.businessinsider.com - May 10 at 8:54 PMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 10 at 8:54 PMRecursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ...finance.yahoo.com - May 10 at 8:54 PMRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Earnings Beatmarketbeat.com - May 10 at 11:23 AMRecursion Pharmaceuticals' (RXRX) "Buy" Rating Reaffirmed at Needham & Company LLCmarketbeat.com - May 10 at 8:55 AMRXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024markets.businessinsider.com - May 9 at 9:55 PMRecursion Provides Business Updates and Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 9 at 4:01 PMRecursion Pharmaceuticals (RXRX) Scheduled to Post Quarterly Earnings on Thursdayamericanbankingnews.com - May 8 at 5:10 AMRecursion (RXRX) to Report Q1 Earnings: What's in the Cards?msn.com - May 6 at 7:23 PMNvidia and a FTSE 100 fund own a 10% stake in this $8 artificial intelligence (AI) stockmsn.com - May 6 at 2:31 AMChristopher Gibson Sells 50,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stockamericanbankingnews.com - May 5 at 5:22 AMVestmark Advisory Solutions Inc. Purchases Shares of 472,256 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)marketbeat.com - May 4 at 2:39 PMInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 50,000 Shares of Stockinsidertrades.com - May 4 at 7:49 AMBlake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stockamericanbankingnews.com - May 4 at 5:32 AMRecursion Pharmaceuticals (RXRX) Scheduled to Post Earnings on Thursdaymarketbeat.com - May 3 at 9:16 AMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Sharesinsidertrades.com - May 3 at 7:30 AMRecursion to Report First Quarter 2024 Business Updates and Financial Results on May 9globenewswire.com - May 2 at 8:00 AMRecursion to Participate in Upcoming Investor Conferencesglobenewswire.com - May 1 at 8:01 AMAltitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Programfinance.yahoo.com - April 30 at 8:37 AMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $23,010.00 in Stockinsidertrades.com - April 30 at 4:23 AMInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 3,000 Shares of Stockmarketbeat.com - April 29 at 7:12 PMThe Top 3 Biotech Stocks to Buy in April 2024investorplace.com - April 27 at 7:00 AMRecursion Pharmaceuticals's Options Frenzy: What You Need to Knowbenzinga.com - April 26 at 8:47 PMRecursion Pharmaceuticals CFO sells shares worth over $367kinvesting.com - April 20 at 1:36 AMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 23,124 Sharesinsidertrades.com - April 19 at 6:53 AMInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stockmarketbeat.com - April 18 at 6:51 PMSumitomo Mitsui Trust Holdings Inc. Buys 5,680,656 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)marketbeat.com - April 18 at 5:57 AMRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Knowfinance.yahoo.com - April 17 at 9:13 PMRecursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officerfinanznachrichten.de - April 17 at 3:44 PMWhere Will Recursion Pharmaceuticals Be in 5 Years?fool.com - April 17 at 10:44 AMRecursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officerglobenewswire.com - April 16 at 8:00 AMRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6%marketbeat.com - April 15 at 5:31 PMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMValidea Detailed Fundamental Analysis - RXRXnasdaq.com - April 10 at 3:25 PMRevisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rateseekingalpha.com - April 10 at 10:25 AMBaillie Gifford & Co. Sells 371,905 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)marketbeat.com - April 10 at 8:24 AMCan Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.fool.com - April 10 at 5:50 AMAnalyst Scoreboard: 5 Ratings For Recursion Pharmaceuticalsmarkets.businessinsider.com - April 9 at 1:46 PMThe AI Advantage: 2 Healthcare Stocks at the Forefront of Innovationfool.com - April 8 at 9:23 AMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $353,600.00 in Stockinsidertrades.com - April 6 at 7:39 AMInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 40,000 Shares of Stockmarketbeat.com - April 5 at 6:39 PMIs This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?fool.com - April 4 at 8:45 AMVanguard Group Inc. Has $118.63 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)marketbeat.com - April 4 at 4:11 AMRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Insider Sellingmarketbeat.com - April 2 at 10:27 AMRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $404,000.00 in Stockinsidertrades.com - April 2 at 4:14 AM Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. RXRX Media Mentions By Week RXRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.610.58▲Average Medical News Sentiment RXRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼195▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fusion Pharmaceuticals News Today Twist Bioscience News Today Schrödinger News Today Ginkgo Bioworks News Today Beam Therapeutics News Today Sana Biotechnology News Today Inhibrx News Today Kymera Therapeutics News Today Apogee Therapeutics News Today ADMA Biologics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingObama’s Forever Term [exposed]Porter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
